Gedeon Richter
Saturday, 28 March
17:15 – 18:00 CET
South Hall 1 (A+B)
in person
Industry Mini Symposium
Sex, Antipsychotics, and Schizophrenia: Addressing an Unspoken Clinical Challenge
Chair: Sofia Pappa, UK
| Introduction | Sofia Pappa, UK |
| Sexual Health in Schizophrenia | Sofia Pappa, UK |
| Sexual Dysfunction and Hyperprolactinaemia Consequences | Angel L. Montejo, Spain |
| Q&A | All |
Dr. Willmar Schwabe GmbH & Co. KG
Sunday, 29 March
13:00 – 13:45 CEST
South Hall 2A
in person
Industry Satellite Symposium
Ahead of the Curve: Early MCI Diagnosis and Management to Protect What Matters
Chair: Professor Dan Rujescu, Austria
| Introduction | Dan Rujescu, Austria |
| Ahead of the Curve: Strategies for Accurate and Early MCI Diagnosis | Dan Rujescu, Austria |
| Changing the Trajectory: Early Intervention Strategies That Can Make a Difference | Robert Perneczky, Germany |
| Live Q & A | All |
Johnson & Johnson
Sunday, 29 March
13:15 – 14:45 CEST
Congress Hall
in person
live streamed
Industry Satellite Symposium
Advancing Outcomes in Depression: Integrating Patient Experience and Evidence-Based Treatment
Chair: Lucie Bartova, Austria
| Welcome and Introduction | Lucie Bartova, Austria |
| What Matters Most: Living With MDD/TRD | Lucie Bartova, Austria Thomas Reinbacher, Germany |
| The Importance of Functional Recovery for QoL and How to Achieve It in MDD/TRD | Bernhard Baune, Germany |
| From MoA to Real-World Impact: Important Considerations When Treating Patients With MDD/TRD | Greg Mattingly, US |
| Audience Q&A | All |
| Closing Remarks | Lucie Bartova, Austria |
ROVI Pharmaceutical Company
Sunday, 29 March
14:00 – 14:45 CEST
South Hall 3
in person
live streamed
Industry Satellite Symposium
The RESHAPE Study: Turning Evidence Into Real Patient Benefits
Chair: Andrea Fiorillo, Italy
| Welcome & RESHAPE’s Aim | Andrea Fiorillo, Italy |
| Effectiveness of Risperidone ISM in Real-Life Patients: Early Discharge and Simplified Treatment Without Concomitant Medication | Miquel Bioque, Spain |
| Risperidone ISM: When Strong Effectiveness Meets Good Tolerability, Enhanced Functioning Follows | Ricardo Moreira, Portugal |
| Open Debate. First-Hand Experiences From Participating Centers | All |
Dr. Willmar Schwabe GmbH & Co. KG
Monday, 30 March
13:00 – 13:45 CEST
South Hall 2A
in person
Industry Satellite Symposium
Individualized Interventions: Towards Personalized Approaches in Anxiety Treatment
Chair: Pavel Mohr, Czeck Republic
| Welcome & Introduction | Pavel Mohr, Czeck Republic |
| From Heterogeneity to Precision: Where Do We Stand in Anxiety? | Andreas Reif, Germany |
| Tailoring Pathways in Anxiety: Evidence, Preferences, Pragmatics | Peter Zwanzger, Germany |
| Q&A | All |
Bristol Myers Squibb
Monday, 30 March
13:15 – 14:45 CEST
Congress Hall
in person
live streamed
Industry Satellite Symposium
Precision Psychiatry in the Age of Muscarinic Agonism
Chair: Christoph Correll, Germany
| Welcome & Introduction | Christoph Correll, Germany Eduard Vieta, Spain Jakub Hort, Czech Republic |
| Mechanisms of Muscarinic Agonism in Neurological and Psychiatric Illnesses | Christoph Correll, Germany |
| Evolving Treatment Landscape and the Potential of Muscarinic Modulators | Christoph Correll, Germany Eduard Vieta, Spain Jakub Hort, Czech Republic |
| Key Takeaways | Christoph Correll, Germany |
| Q&A | Christoph Correll, Germany Eduard Vieta, Spain Jakub Hort, Czech Republic |
| Closing Remarks | Christoph Correll, Germany |
Idorsia Pharmaceuticals Ltd
Monday, 30 March
13:15 – 14:45 CEST
Forum Hall
in person
live streamed
Industry Satellite Symposium
Managing Insomnia Disorder in Psychiatric Practice: From Anxiety to Abuse Risk
Chair: Andrea Fiorillo, Italy
| Insomnia Disorder: Why Psychiatrists Must Act Now | Andrea Fiorillo, Italy |
| Managing Insomnia Disorder in Complex Psychiatric Profiles: From Anxiety to Substance Use Disorder | Göran Hayak, Germany |
| Targeting the Wake System: Daridorexant Updates and Safety Insights | William Vaughn McCall, US |
| Real-World Evidence: Insomnia Disorder in Patients with Anxiety, Depression, or Substance Use Disorders | Laura Palagini, Italy |
| Clinical Case: Practical Management of Insomnia Disorder in A Psychiatric Patient | David O’Regan, UK |
| Panel Discussion & Q&A: Insomnia Disorder in the Complexity of the Psychiatric Clinic – Where Do We Go Next? | All |